First Hawaiian Bank Sells 5,571 Shares of Danaher Co. (NYSE:DHR)

First Hawaiian Bank lessened its stake in shares of Danaher Co. (NYSE:DHR) by 76.6% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,705 shares of the conglomerate’s stock after selling 5,571 shares during the quarter. First Hawaiian Bank’s holdings in Danaher were worth $426,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in DHR. ST Germain D J Co. Inc. increased its holdings in shares of Danaher by 1.4% in the first quarter. ST Germain D J Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Godsey & Gibb Inc. increased its holdings in Danaher by 3.0% in the 1st quarter. Godsey & Gibb Inc. now owns 1,442 shares of the conglomerate’s stock worth $360,000 after buying an additional 42 shares during the period. Nicholas Hoffman & Company LLC. raised its position in Danaher by 2.3% during the 4th quarter. Nicholas Hoffman & Company LLC. now owns 1,899 shares of the conglomerate’s stock worth $439,000 after buying an additional 43 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in Danaher by 1.3% during the 4th quarter. Los Angeles Capital Management LLC now owns 3,470 shares of the conglomerate’s stock valued at $803,000 after acquiring an additional 43 shares during the period. Finally, Berger Financial Group Inc boosted its holdings in shares of Danaher by 1.7% in the 4th quarter. Berger Financial Group Inc now owns 2,517 shares of the conglomerate’s stock valued at $582,000 after acquiring an additional 43 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Jefferies Financial Group initiated coverage on shares of Danaher in a research report on Monday, June 3rd. They set a “buy” rating and a $295.00 target price for the company. Citigroup upped their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. TD Cowen boosted their price target on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, July 24th. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Six equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $276.88.

Insider Transactions at Danaher

In other Danaher news, Director Linda Filler sold 3,928 shares of the firm’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $279.50, for a total value of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares of the company’s stock, valued at approximately $11,501,145.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at approximately $28,352,350. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Linda Filler sold 3,928 shares of the company’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the sale, the director now directly owns 41,149 shares in the company, valued at $11,501,145.50. The disclosure for this sale can be found here. Over the last three months, insiders have sold 113,174 shares of company stock valued at $29,775,644. Corporate insiders own 11.10% of the company’s stock.

Danaher Price Performance

DHR stock traded up $3.17 during trading on Tuesday, hitting $272.49. The stock had a trading volume of 1,259,405 shares, compared to its average volume of 2,900,006. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $281.70. The company’s 50-day moving average price is $256.42 and its two-hundred day moving average price is $251.43. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock has a market capitalization of $196.80 billion, a P/E ratio of 46.31, a PEG ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The business’s revenue was down 2.9% on a year-over-year basis. As a group, research analysts predict that Danaher Co. will post 7.59 EPS for the current fiscal year.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.